Rheumatic-Heart Disease Management Market by Type, Application & Region | Forecast 2023 to 2033
The government's increased healthcare spending to combat the growing incidence of rheumatic heart disease is one of the major factors accelerating the growth of the Rheumatic-Heart Disease Management Market during the forecast period.
Rheumatic-Heart Disease Management Market Snapshot (2023 to 2033)
The global Rheumatic-Heart Disease Management market size is expected to be valued at US$ 1.31 Billion in 2023. With the continuous improvements in drugs and biotechnology, the overall demand for Rheumatic-Heart Disease Management is projected to grow at a CAGR of 4.5% between 2023 and 2033, totaling around US$ 2.04 Billion by 2033.
Data Points
Key Statistics
Rheumatic-Heart Disease Management Market Value 2023
US$ 1.31 Billion
Rheumatic-Heart Disease Management Market Projected Value (2033)
US$ 2.04 Billion
Rheumatic-Heart Disease Management Market CAGR (2023 to 2033)
4.5%
According to the analysis of Future Market Insights, rheumatic fever is an autoimmune inflammatory disease that can develop as a complication of inadequately treated strep throat. Strep throat is a condition caused by group a of the Streptococcus bacterium. Rheumatic fever is common in the age group of 5 to 15 years, but adults can also have the condition. In certain cases, rheumatic fever can cause long-term damage to the heart and heart valves.
According to the World Health Organization (WHO) report published in April 2018, approximately 30 million people are affected by rheumatic heart disease globally. The increasing occurrences of strep throat and the growing prevalence of rheumatic fever are the major factors that are anticipated to boost the growth of the rheumatic heart disease management market over the analysis period. Additionally, another factor including increasing government expenditure for the healthcare sector is also expected to contribute to the market growth in the near future.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Rheumatic-Heart Disease Management Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for Rheumatic-Heart Disease Management is projected to increase at a CAGR of 4.5% during the forecast period between 2023 and 2033, reaching a total of US$ 2.04 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 2.1%.
According to Future Market Insights, a market research and competitive intelligence provider, the Rheumatic-Heart Disease Management market was valued at US$ 1.25 Billion in 2022.
In developing economies, rheumatic fever is highly prevalent and remains one of the major causes of rheumatic heart disease. Rheumatic fever is a major cause of mortality among people aged 50 years and above. According to the United Nations Department of Economic and Social Affairs, in 2015, the global population aged 60 years and above was approximately 901 million, and the number is expected to increase significantly over the analysis period.
The population aged 50 years and above has a higher incidence of rheumatic heart disease and mortality rates as compared to younger people. The incidence rate of rheumatic fever is higher in developing countries as compared to developed countries.
According to the Centers for Disease Control and Prevention (CDC), about 23% of adults in the USA, which is over 54 million people, have arthritis. By 2040, the disease is expected to affect 78 million adults in the country. Rheumatic fever is a leading cause of disability. The direct medical costs associated with the disease are over US$ 81 Mn annually. This disease is more common in women than in men.
Which Drivers underpin Rheumatic-Heart Disease Management Industry Expansion?
Increasing prevalence of Strep Throat and Rheumatic Feverto Fuel the Market Growth
The rising incidences of strep throat are one of the major factors that are projected to augment the growth of the rheumatic heart disease management market during the forecast period. Rheumatic fever is an autoimmune inflammatory disease that can develop as a result of strep throat that hasn't been properly treated. Strep throat is a bacterial infection caused by the Streptococcus bacteria of group A.
It is highly common in low- and middle-income countries, due to a lack of proper sanitation, and healthcare awareness in these countries. According to the statistics by the World Health Organization (WHO), rheumatic heart diseases, such as rheumatic myocarditis is responsible for over 288 348 deaths each year, as of 2020.
Rise in Research & Development Activities to Accelerate the Market Growth
The growth of the rheumatic heart disease management market will also be driven by an increase in the number of research and development activities, which in turn are expected to provide beneficial opportunities for market growth in the coming years. In addition, factors such as a rise in government initiatives, improved healthcare infrastructure, and an increase in the number of emerging markets are expected to create lucrative avenues for market growth during the forecast period.
Additionally, a rise in investment in the healthcare sector in developing countries, and government initiatives to curb the spread of streptococcus bacteria, are expected to accelerate the market growth. For instance, in 2018, the WHO launched a coordinated global response for rheumatic heart disease and rheumatic fever, with the help of WHO’s regional offices. The program includes a road map for the distribution of medicines, vaccines, and other healthcare products by 2023.
Find your sweet spots for generating winning opportunities in this market.
Which Factors are limiting the Growth of Rheumatic-Heart Disease Management Market?
Lack of Awareness in Low-and-Middle-Income Countries to Restrain the Market Growth
Lack of Awareness regarding the treatment of rheumatic heart disease is one of the major factors that is expected to impede the growth of the Rheumatic-Heart Disease Management Market over the analysis period.
Moreover, the dearth of skilled professionals and lack of healthcare infrastructure in developing economies are other factors that are expected to challenge market growth. In addition, the high cost associated with the treatment of rheumatic heart disease will obstruct the growth rate of the market.
Fewer Treatment Options to Limit the Market Growth
Factors including fewer treatment options available for the treatment of rheumatic heart disease management are likely to hinder the growth of the Rheumatic-Heart Disease Management market in the forthcoming years.
Moreover, rheumatic heart disease can be prevented by effective management of streptococcal sore throat, however, treatment at this early stage is often not achieved. Families may not have the time or money to access a healthcare facility, or may not seek care due to low awareness of the potential risk of untreated ‘strep throat’. Healthcare workers may also not have the necessary knowledge to appropriately diagnose and manage ‘strep throat’. If left untreated, rheumatic fever may then ensue. This in turn is anticipated to hamper the market growth during the forecast period.
Region-wise Insights
Will North America Continue Dominance in the Global Rheumatic-Heart Disease Management Market?
Increase in Prevalence of Rheumatic Fever in the Region to Fuel the Market Growth
The Rheumatic-Heart Disease Management Market in North America is expected to accumulate the highest market share of 45% in 2023.
Factors such as the increasing prevalence of rheumatic fever and the growing focus of major key players on novel technology are expected to boost the regional market growth over the analysis period. Favorable health reimbursement, an increasing number of valve repair and replacement procedures, and a rising obese population are other factors responsible for the market growth in the region.
According to the American Heart Association, 90,000 valve substitutes are implanted in the USA every year. This is poised to surge the demand for prosthetic heart valves in North America, which in turn is anticipated to fuel the market growth. The region is expected to hold the highest CAGR of 4.4% during the forecast period.
How Will the Growth of the Rheumatic-Heart Disease Management Market unfold in Europe?
Rising Prevalence of Rheumatic Heart Disease in the Region to Fuel the Market Growth
The Rheumatic-Heart Disease Management Market in Europe is expected to accumulate the highest market share of 44% in 2023.
In Europe, the market is estimated to expand, attributed to the factors such as the increasing prevalence of rheumatic heart disease and the gradual shift towards minimally invasive procedures. According to the European Society of Cardiology, in 2017, the average proportion of males and females with elevated blood pressure in Europe was 28% and 20% respectively. This is expected to foster the prosthetic Heart Valves Market in Europe.
Moreover, the regional market is projected to grow, owing to the rising geriatric and obese population, rapid adoption of tissue valves, and active government support. The region is expected to hold the highest CAGR of 4.3% during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
By Type, which Rheumatic-Heart Disease Management Category will remain prominent?
Valve Segment to beat Competition in Untiring Market
On the basis of type, the global Rheumatic-Heart Disease Management market is dominated by the Valve Segment, which accounts for a share of 46%. The segment is expected to hold a CAGR of 4.4% over the analysis period.
The high segment’s growth is attributed to factors such as the introduction of new products in the market. Already, the introduction of tissue valves has revolutionized the prosthetic heart valves, which in turn is expected to boost the segment’s growth.
Now, with the launch of products that are minimally invasive and sutureless, the rheumatic heart disease market is expected to gain significant traction. In addition, many manufacturers are carrying out dedicated research and clinical trial for the development of innovative heart valves.
By Application, which Rheumatic-Heart Disease Management Category to dominate?
Hospitals Segment to Drive the Rheumatic-Heart Disease Management Market
Based on the Application, the hospital's segment is expected to witness a significant growth of 46% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.3% CAGR over the analysis period.
The segment’s significant growth is attributed to the factors such as the increasing number of procedures in hospitals, favorable health reimbursement, and improving government guidelines for the management of vulvar diseases, which are contributing to the expansion of the market growth.
The Start-up Ecosystem: How key Players are opening Frontiers for Future Growth?
Rheumatic-Heart Disease Management Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,
Founded in 2016, Croivalve is a developer of a percutaneous device for treating tricuspid regurgitation. The device seals the gap between the valve leaflets preventing regurgitation. The device is delivered through a vein and into the right heart, restoring the function of the tricuspid valve.
Micro Interventional, started in 2010, is developing technologies for percutaneous and minimally invasive structural heart repair procedures. The company has two products - Permaseal, an implant for wound closure for structural heart repair procedures, and Endovalve, a mitral valve replacement system. Products are yet to be approved for commercial use.
In 2020, CardioMech, a Transcatheter Mitral Valve Repair Startup announced it had closed on its Series A financing led by a non-disclosed strategic investor together with healthcare specialist investor Hadean Ventures and Investinor. The $18.5 million in financing funded its first-in-human feasibility trial.
Who are the Leading Players in the Rheumatic-Heart Disease Management Market?
Prominent players in the Rheumatic-Heart Disease Management market are F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc., Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., Allergan, AstraZeneca, AbbVie Inc., Johnson & Johnson Private Limited, Cipla Inc., Abbott, Merck KGaA, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Limited, Amneal Pharmaceuticals LLC., and Bayer AG, among others.
Recent Developments:
In May 2022, Cardiol Therapeutics announced FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of Cardiolrx for recurrent pericarditis.
In March 2021, Kiniksa Pharmaceuticals, Ltd. reported the United States Food and Drug Administration (FDA) approved ARCALYST (rilonacept), a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling, for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older.
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 4.5% from 2023 to 2033
Market Value in 2023
US$ 1.31 Billion
Market Value in 2033
US$ 2.04 Billion
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Type
Application
Region
Regions Covered
North America
Europe
Europe
Latin America
Middle East & Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
China
Japan
South Korea
Malaysia
Singapore
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Pfizer Inc.
GlaxoSmithKline plc.
Novartis AG
Bayer AG
Eli Lilly and Company
Merck & Co., Inc.
Allergan
AstraZeneca
AbbVie Inc.
Johnson & Johnson Private Limited
Cipla Inc.
Abbott
Merck KGaA
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Dr. Reddy’s Laboratories Ltd.
Glenmark Pharmaceuticals Limited
Amneal Pharmaceuticals LLC.
Bayer AG
Key Segments Covered in the Rheumatic-Heart Disease Management Industry Analysis
Rheumatic-Heart Disease Management Market by Type:
Valve
Myocarditis
Pericarditis
Rheumatic-Heart Disease Management Market by Application:
Hospital
Diagnostic Centre
Research Centre
Rheumatic-Heart Disease Management Market by Region:
North America
Europe
Europe
Latin America
Middle East & Africa
Frequently Asked Questions
How Big is the Rheumatic-Heart Disease Management Market?
The market is valued at US$ 1.31 billion in 2023.
Who are the Leading Industry Players?
F. Hoffmann-La Roche Ltd., Mylan N.V., and Teva Pharmaceutical Industries Ltd. are the leading industry players.
What is the Growth Forecast for the Rheumatic-Heart Disease Management Industry until 2033?
The industry is set to surge at a CAGR of 4.5% from 2023 to 2033.
What is North America's Expected Market Share until 2023?
North America is likely to generate 45% revenue in 2023.
Which is the Top Trend in the Rheumatic-Heart Disease Management Market?
Rising incidence of strep throat and rheumatic fever driving the expansion of the market
Table of Content
1. Executive Summary | Rheumatic-Heart Disease Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Billion) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Billion) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Billion) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Type, 2023 to 2033
5.3.1. Valve
5.3.2. Myocarditis
5.3.3. Pericarditis
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Billion) Analysis By Application, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Application, 2023 to 2033
6.3.1. Hospital
6.3.2. Diagnostic Centre
6.3.3. Research Centre
6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Billion) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Billion) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa(MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Type
8.2.3. By Application
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type
8.3.3. By Application
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Type
9.2.3. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Application
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Type
10.2.3. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Application
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Type
11.2.3. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Application
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of Middle East and Africa(MEA)
12.2.2. By Type
12.2.3. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Application
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Type
13.1.2.2. By Application
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Type
13.2.2.2. By Application
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Type
13.3.2.2. By Application
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Type
13.4.2.2. By Application
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Type
13.5.2.2. By Application
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Type
13.6.2.2. By Application
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Type
13.7.2.2. By Application
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Type
13.8.2.2. By Application
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Type
13.9.2.2. By Application
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Type
13.10.2.2. By Application
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Type
13.11.2.2. By Application
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Type
13.12.2.2. By Application
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Type
13.13.2.2. By Application
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Type
13.14.2.2. By Application
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Type
13.15.2.2. By Application
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Type
13.16.2.2. By Application
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Type
13.17.2.2. By Application
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Type
13.18.2.2. By Application
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Type
13.19.2.2. By Application
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Type
13.20.2.2. By Application
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Type
14.3.3. By Application
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Abbott Laboratories
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Bayer
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. BIOTRONIK
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Boston Scientific
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Bristol-Myers Squibb
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Cardinal Health
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Cook Medical
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Roche
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. GE Healthcare
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Novartis
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used17. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Billion) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Billion) Forecast by Type, 2018 to 2033
Table 3: Global Market Value (US$ Billion) Forecast by Application, 2018 to 2033
Table 4: North America Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Billion) Forecast by Type, 2018 to 2033
Table 6: North America Market Value (US$ Billion) Forecast by Application, 2018 to 2033
Table 7: Latin America Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Billion) Forecast by Type, 2018 to 2033
Table 9: Latin America Market Value (US$ Billion) Forecast by Application, 2018 to 2033
Table 10: Europe Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Billion) Forecast by Type, 2018 to 2033
Table 12: Europe Market Value (US$ Billion) Forecast by Application, 2018 to 2033
Table 13: Asia Pacific Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Market Value (US$ Billion) Forecast by Type, 2018 to 2033
Table 15: Asia Pacific Market Value (US$ Billion) Forecast by Application, 2018 to 2033
Table 16: MEA Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 17: MEA Market Value (US$ Billion) Forecast by Type, 2018 to 2033
Table 18: MEA Market Value (US$ Billion) Forecast by Application, 2018 to 2033
List of Charts
Figure 1: Global Market Value (US$ Billion) by Type, 2023 to 2033
Figure 2: Global Market Value (US$ Billion) by Application, 2023 to 2033
Figure 3: Global Market Value (US$ Billion) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Billion) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Billion) Analysis by Type, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 10: Global Market Value (US$ Billion) Analysis by Application, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 13: Global Market Attractiveness by Type, 2023 to 2033
Figure 14: Global Market Attractiveness by Application, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Billion) by Type, 2023 to 2033
Figure 17: North America Market Value (US$ Billion) by Application, 2023 to 2033
Figure 18: North America Market Value (US$ Billion) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Billion) Analysis by Type, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 25: North America Market Value (US$ Billion) Analysis by Application, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 28: North America Market Attractiveness by Type, 2023 to 2033
Figure 29: North America Market Attractiveness by Application, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Billion) by Type, 2023 to 2033
Figure 32: Latin America Market Value (US$ Billion) by Application, 2023 to 2033
Figure 33: Latin America Market Value (US$ Billion) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Billion) Analysis by Type, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 40: Latin America Market Value (US$ Billion) Analysis by Application, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Type, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Application, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Billion) by Type, 2023 to 2033
Figure 47: Europe Market Value (US$ Billion) by Application, 2023 to 2033
Figure 48: Europe Market Value (US$ Billion) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Billion) Analysis by Type, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 55: Europe Market Value (US$ Billion) Analysis by Application, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 58: Europe Market Attractiveness by Type, 2023 to 2033
Figure 59: Europe Market Attractiveness by Application, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Market Value (US$ Billion) by Type, 2023 to 2033
Figure 62: Asia Pacific Market Value (US$ Billion) by Application, 2023 to 2033
Figure 63: Asia Pacific Market Value (US$ Billion) by Country, 2023 to 2033
Figure 64: Asia Pacific Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Market Value (US$ Billion) Analysis by Type, 2018 to 2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 70: Asia Pacific Market Value (US$ Billion) Analysis by Application, 2018 to 2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 73: Asia Pacific Market Attractiveness by Type, 2023 to 2033
Figure 74: Asia Pacific Market Attractiveness by Application, 2023 to 2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: MEA Market Value (US$ Billion) by Type, 2023 to 2033
Figure 77: MEA Market Value (US$ Billion) by Application, 2023 to 2033
Figure 78: MEA Market Value (US$ Billion) by Country, 2023 to 2033
Figure 79: MEA Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Market Value (US$ Billion) Analysis by Type, 2018 to 2033
Figure 83: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 85: MEA Market Value (US$ Billion) Analysis by Application, 2018 to 2033
Figure 86: MEA Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 87: MEA Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 88: MEA Market Attractiveness by Type, 2023 to 2033
Figure 89: MEA Market Attractiveness by Application, 2023 to 2033
Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
